Welcome to the MarketReader Minute.

Below are AI-generated insights on today's premarket moves, powered by MarketReader technology.

Monday, October 12

Noteworthy macro moves today: Noteworthy US mega-cap moves today: Meta Platforms Inc (META) +1.3%. AbbVie Inc (ABBV) +0.7%. Berkshire Hathaway Inc (BRK.B) +0.4%.

Global equity indices are trading higher today, although cash markets in the United States, Canada, Japan, and Spain are closed for public holidays. In Asia, markets are generally up despite mixed performances within the region; South Korea's Kospi fell sharply due to concerns over the semiconductor sector while other indices like Australia's S&P/ASX 200 gained notably.

In China, vehicle sales dropped by 8.4% year-on-year in September, a steeper decline than the previous month's drop of 5.1%. This significant contraction in car sales reflects ongoing challenges in consumer demand amid broader economic uncertainties.

U.S. Treasury yields reached their highest levels since 2002 at around 5.24%, contributing to investor caution ahead of upcoming inflation data releases this week that could influence Federal Reserve policy decisions. The market anticipates a Consumer Price Index (CPI) increase to approximately 3.7% for September when it is released on October 14.

Recent geopolitical tensions have also impacted market sentiment; President Trump's announcement regarding a diesel deal with Russia aimed at stabilizing fuel prices has been met with mixed reactions as conflicts involving Iranian proxies continue to threaten energy supply routes.

iShares MSCI South Korea ETF (EWY) [-2.3%]
The iShares MSCI South Korea ETF is trading lower in pre-market hours, driven by sharp declines in key holdings, particularly Korea Electric Power Corp (KEP) and SK hynix (SKHY). KEP has been on a downward trend since Friday, contributing to the ETF's overall decline. Other holdings did not exhibit significant news to counterbalance this movement. The fund's current price is notably below its 20-day moving average and near the lower end of its one-month range.

VanEck Gold Miners ETF (GDX) [-1.0%]
The VanEck Gold Miners ETF declined in pre-market trading, driven by losses in key holdings including Agnico Eagle Mines, Newmont Corporation, and Barrick Gold, amid escalating geopolitical tensions following missile attacks on Saudi Arabia's aviation infrastructure. This environment contributed to a drop in gold prices. The fund's performance aligns with a slight decrease in gold prices, which are influenced by broader market trends and concerns about energy supply stability. In this context, GDX is trading lower and remains near the lower end of its recent trading range.

VanEck Semiconductor ETF (SMH) [-0.8%]
Concerns over AI revenue projections have led to significant declines in semiconductor stocks, impacting the VanEck Semiconductor ETF, which is trading modestly lower in pre-market hours. Key holdings such as Micron Technology, Marvell Technology, Intel, Advanced Micro Devices, and Applied Materials contributed to this pullback. Reports indicate that OpenAI's annualized revenue is significantly lower than previously expected, affecting semiconductor valuations tied to AI infrastructure spending. Social media posts highlight a recent recovery from a previous low, with users discussing the potential for institutional buying at this level. However, some users noted that SMH has faced challenges compared to other sectors, particularly software, while broader market indices like the Nasdaq have reached all-time highs.

CRM | +4.0% | +7.8B
Salesforce Inc | Information Technology
BofA Securities upgraded Salesforce Inc to Buy from Underperform and raised its price target to $285 from $160 in a report published today, contributing to a pre-market increase in the company's shares. The upgrade has been positively received, with additional reports confirming the revised outlook. In related social media activity, CEO Marc Benioff announced the launch of AIForce, rebranded as "SIForce," and emphasized the arrival of "Super Intelligence." Users on X noted the sharp rise in Salesforce shares following the upgrade and highlighted Benioff's comments about AI initiatives.

BMY | +3.6% | +4.6B
Bristol-Myers Squibb Co | Health Care
Bristol-Myers Squibb Co announced that its Phase 3 ALOFT-IPF trial for admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint, demonstrating a statistically significant improvement in forced vital capacity at the 60 mg dose compared to placebo. The trial involved around 1.25k participants and reported a favorable safety profile. Additionally, the company revealed positive topline results from the interim analysis of the ACTION-1 trial for RYZ101, which also met its primary endpoint by showing significant improvement in progression-free survival for patients with gastroenteropancreatic neuroendocrine tumors. Social media posts highlighted these developments, with users discussing the positive topline results from both trials. In pre-market hours, shares are gaining, reflecting a notable increase since Friday's close.

FSLR | +3.5% | +0.7B
First Solar Inc | Information Technology
First Solar Inc shares advanced following an upgrade from Truist Securities, which raised its rating to Buy and increased the price target to $270. The upgrade reflects growing confidence in the company's prospects within the renewable energy sector. As a result, shares were already up earlier in pre-market trading. The company has a contracted backlog of $13.6 billion through 2030, providing substantial revenue visibility despite potential challenges. In addition, recent U.S. trade actions and Section 45X credits have created a domestic cost advantage for First Solar against its competitors.

MANH | +3.8% | +0.5B
Manhattan Associates Inc | Information Technology
Morgan Stanley upgraded Manhattan Associates Inc from Equalweight to Overweight, increasing its price target to $250.00 from $180.00. The upgrade was announced at 7:55 AM ET today. In pre-market trading, shares of Manhattan Associates are advancing. The stock is also moving higher alongside Salesforce Inc, which has risen sharply following an upgrade from BofA Securities to Buy from Underperform.

BMRN | +2.9% | +0.3B
BioMarin Pharmaceutical Inc | Health Care
BioMarin Pharmaceutical Inc received an upgrade from Raymond James, moving from Outperform to Strong Buy, with a new price target set at $109.00. This announcement was made today at 7:55 AM ET. In pre-market trading, shares of BioMarin are advancing, showing a notable increase since Friday's close. The stock's current performance reflects a shift from earlier fluctuations that had seen it dip slightly below the previous close. BioMarin is expected to present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting in Boston, including results from studies of VOXZOGO® in children with achondroplasia and hypochondroplasia.

Thank you for spending a minute with us.

If you have 2 more minutes, watch this demo of the MarketReader Platform: